## Please amend the specification as follows:

B

Page 1, line 2, please add a new paragraph, -- This application claims priority from Provisional Application Number(s) 60/117,814, filed January 28, 1999; and 60/157,288, filed October 1, 1999. --

Page 21, line 22, after "2070" add --(SEQ ID NO. 1)--.

Page 21, line 25, after "3498" add --(SEQ ID NO. 2)--.

Page 22, line 11, after "2047" add --(SEQ ID NO. 3)--.

Page 22, line 13, after "2002" add --(SEQ ID NO. 4)--.

Page 22, line 26, after "2272" add --(SEQ ID NO. 5)--.

Page 22, line 30, after "2202" add --(SEQ ID NO. 6)--.

Page 23, line 7, after "1361" add --(SEQ ID NO. 7)--.

Page 23, line 10, after "3498" add --(SEQ ID NO. 8)--.

Page 23, line 26, after "4077" add --(SEQ ID NO. 9)--.

Page 23, line 30, after "4021" add --(SEQ ID NO. 10)--.

Page 24, line 14, after "1655" add --(SEQ ID NO. 11)--.

Page 24, line 16, after "2911" add --(SEQ ID NO. 12)--.

## In the Claims,

Please amend the claims as follows:

200 1.

(Amended) A recombinant adenoviral vector comprising a deletion of E1b region gene(s), but retaining the E1b promoter, and [optionally, the substitution]

Attorney Docket No.: ONYX1022 ONYX1022ord/Responses/1022-Resp1 100.003 11/14/2000-2:36 PM